Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02572947
Other study ID # PRD-13-2015-I
Secondary ID
Status Completed
Phase Phase 2
First received October 7, 2015
Last updated October 31, 2017
Start date June 2016
Est. completion date September 2017

Study information

Verified date October 2017
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current HIV treatment guidelines recommend a combination of drugs for the maintenance of antiretroviral therapy (ART). Simplification is considered critical to further scale-up of treatment, to support retention in care and to reduce costs. Dolutegravir is a once daily integrase inhibitor that shows very good tolerability, efficacy, and distinctive resistance profile. The researchers aim at investigating the feasibility of dolutegravir monotherapy in maintenance therapy. Briefly, 10 virologically suppressed patients for at least six months on conventional triple ART of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) will be switched to dolutegravir monotherapy for 24 weeks. The primary endpoint is the number of patients completing 24 weeks of dolutegravir monotherapy without experiencing virological failure.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date September 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- HIV-1 infection;

- Patient included in the Swiss HIV Cohort Study (SHCS);

- = 18 years of age;

- Virologically suppressed for at least 24 months on first line triple ART (changes for toxicity permitted) with at least 4 HIV-1 RNA measurements in plasma <50 copies/ml;

- No history of previous failure on ART;

- No documented antiretroviral drugs resistance;

- No co-infection with Hepatitis B or C virus;

- Effective contraception in women;

- Willing to provide CSF and semen samples;

- Written informed consent

Exclusion Criteria:

- HIV-2 infection;

- Renal dysfunction (creatinine clearance <50ml/min);

- aspartate transaminase or alanine aminotransferase >5x upper limit normal;

- Concomitant use of carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's wort, rifampicin or metformin;

- Previous AIDS defining conditions or active malignancy in the past five years;

- Positive HIV viral load in CSF at baseline;

- Known or suspected non-compliance;

- Women who are pregnant or breastfeeding.

Study Design


Intervention

Drug:
Dolutegravir


Locations

Country Name City State
Switzerland University Hospitals of Geneva, HIV unit Geneva

Sponsors (1)

Lead Sponsor Collaborator
Calmy Alexandra

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in immune activation from baseline to week 24 measured by highly sensitive C-reactive protein (mg/l) week 24
Other Change in immune activation from baseline to week 24 measured by cytokines (pg/ml) week 24
Other Change in immune activation from baseline to week 24 measured by d-dimers (microg/l) week 24
Primary Number of patients without virological failure defined as plasma HIV-1 RNA = 200 copies/ml on two consecutive measurements or positive HIV-1 RNA level in cerebrospinal fluid (CSF) at week 24 or before week 24
Secondary Quantification of the HIV-1 DNA reservoir in peripheral blood monocyte cells at baseline and week 24 week 24
Secondary Emergence of genotypic resistance in plasma HIV-1 RNA in case of virological failure week 24
Secondary Quantification HIV-1 RNA levels in the CSF and semen at baseline and week 24 Lumbar puncture is optional at baseline week 24
Secondary Change from baseline CD4 cell count from baseline at week 24 week 24
Secondary Adherence to medication at weeks 4, 8, 12, 16, 20, 24 Number of participants with suboptimal adherence defined as more than 3 pills (10%) remaining from previous monthly visit OR missed more than one dose in a row OR missed dose more than once every two weeks week 24
Secondary Lipidic profile changes from baseline at week 24 week 24
Secondary Body fat composition as measured by dual energy x-ray absorptiometry (DXA) scan at baseline and week 24 week 24
Secondary Change in bone mineral density from baseline to week 24 Number of patients with normal bone density, osteopenia or osteoporosis as defined by DXA scans results week 24
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1